Who are UC-MSC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Allogenix Plus, Stempeucel®, MC, SkinTE, Autologous platelets rich plasma.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/uc-msc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

UC-MSC — Competitive Intelligence Brief

UC-MSC (UC-MSC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy; mesenchymal stem cell product. Area: Regenerative Medicine; Immunology.

phase 3 Cell therapy; mesenchymal stem cell product Regenerative Medicine; Immunology Biologic Live · refreshed every 30 min

Target snapshot

UC-MSC (UC-MSC) — PT. Prodia Stem Cell Indonesia. UC-MSC is an umbilical cord-derived mesenchymal stem cell therapy that promotes tissue regeneration and modulates immune responses through paracrine signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
UC-MSC TARGET	UC-MSC	PT. Prodia Stem Cell Indonesia	phase 3	Cell therapy; mesenchymal stem cell product
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Allogenix Plus	Allogenix Plus	University of Missouri-Columbia	marketed	Allogeneic cell therapy
Stempeucel®	Stempeucel®	Cell Biopeutics Resources Sdn Bhd	marketed	Allogeneic mesenchymal stem cell therapy
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy
SkinTE	SkinTE	PolarityTE	marketed	Autologous cell therapy / Tissue-engineered product
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy; mesenchymal stem cell product class)

PT. Prodia Stem Cell Indonesia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). UC-MSC — Competitive Intelligence Brief. https://druglandscape.com/ci/uc-msc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab